ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,200.79
-2.21%
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs Yen
156.747
0.67%
Brent Oil
79.405
-0.59%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Denali Therapeutics Inc (DNLI)

  7. Denali Therapeutics Inc (DNLI) ニュース

DNLI

Denali Therapeutics (DNLI)

Denali Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:DNLI
日付受信時刻ニュースソース見出しコード企業名
2024/06/0705 : 26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/06/0507 : 32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/06/0507 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/06/0507 : 27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/06/0321 : 00GlobeNewswire Inc.Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease TherapiesNASDAQ:DNLIDenali Therapeutics Inc
2024/06/0105 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
2024/05/0805 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
2024/05/0805 : 01GlobeNewswire Inc.Denali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
2024/05/0121 : 00GlobeNewswire Inc.Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialNASDAQ:DNLIDenali Therapeutics Inc
2024/03/0206 : 51Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:DNLIDenali Therapeutics Inc
2024/02/2722 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
2024/02/2722 : 05GlobeNewswire Inc.Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:DNLIDenali Therapeutics Inc
2024/02/2722 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
2024/02/2722 : 00GlobeNewswire Inc.Denali Therapeutics Announces $500 million Private Placement Equity FinancingNASDAQ:DNLIDenali Therapeutics Inc
2024/02/1622 : 02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DNLIDenali Therapeutics Inc
2024/02/1611 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/02/1611 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/02/1611 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/02/1506 : 59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/02/1506 : 43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/02/1410 : 19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/02/1410 : 18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/02/1410 : 17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/02/1306 : 48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/02/0722 : 00GlobeNewswire Inc.Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
2024/02/0122 : 00GlobeNewswire Inc.Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™NASDAQ:DNLIDenali Therapeutics Inc
2024/01/1310 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/01/1207 : 28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/01/1106 : 09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DNLIDenali Therapeutics Inc
2024/01/1009 : 35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DNLIDenali Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:DNLI

最近閲覧した銘柄

USI
USTECH100
US Tech 100
AMEX
XLF
Financial Select Sector
NYSE
CVX
Chevron
NASDAQ
NVDA
NVIDIA
USOTC
RHHBY
Roche (QX)
CCOM
SILVER
SILVER
COIN
BTCUSD
Bitcoin
PM
XAUUSD
Gold vs US Dollar
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
NKE
Nike
CCOM
US100
US Tech 100
NASDAQ
MSFT
Microsoft
COIN
SOLUSD
Solana
FX
USDGBP
US Dollar vs Sterling
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有